Table 1. Comparison of Chang et al. (1) data with SABR results for medically-operable patients with esNSCLC.
| Study | N | Eligible | Treatment | Age | Median follow-up (months) | Local or lobar failure | Regional failures | Distant failures | PFS | OS | Toxicity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chang (1), Lobectomy Cohort Phase III |
27 | Operable T1-2a N0 |
Lobectomy | 67 | 35.4 | 3-year 0% |
3-year 4% |
3-year 9% |
3-year 80% |
3-year 79% |
Grade ≥3 (48%) 1 Grade 5 |
| Chang (1), SABR Cohort Phase III |
31 | Operable T1-2a N0 |
54 Gy (3 fractions); 50 Gy (3 fractions); 60 Gy (3 fractions) |
67 | 40.2 | 3-year 4% |
3-year 10% |
3-year 3% |
3-year 86% |
3-year 95% |
Grade 3 (10%) |
| Timmerman (6), RTOG 0618 Phase II |
26 | Operable T1-2 N0 |
54 Gy (3 fractions) | 72 | 25 | 2-year 20% |
2-year 12% |
2-year 15% |
2-year 65% |
2-year 84% |
Grade 3 (16%) |
| Lagerwaard (7), Retrospective |
177 | Operable T1-T2 N0 |
60 Gy (risk-adapted to 3, 5, or 8 fractions) | 76 | 31.5 | 3-year 7% |
3-year 10% |
3-year 10% |
3-year 81% |
3-year 85% |
Grade ≥3 pneumonitis in 2% and rib fracture 3% |
| Onishi (8), Retrospective |
87 | Operable T1-2 N0 |
45-72.5 Gy at isocenter (3-10 fractions) | 74 | 55 | 5-year 13% |
5-year 15% |
5-year 25% |
NR | 5-year 70% |
Grade 3 (8.2%) |
SABR, stereotactic ablative radiotherapy; esNSCLC, early stage non-small cell lung cancer; PFS, progression-free survival; OS, overall survival; NR, not reported.